Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
This article was originally published in The Pink Sheet Daily
Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.
You may also be interested in...
A Closer Look: Ambrx Doubles Down In China With Hisun Deal
San Diego-based Ambrx is aggressively striking deals with companies in China. PharmAsia News takes a closer look at a recent deal with Hisun and adds background to its growing ties to Big Pharma.
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.